InDex Pharmaceuticals Holding AB
https://www.indexpharma.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From InDex Pharmaceuticals Holding AB
Disappointed InDex CONCLUDEs Development Of Ulcerative Colitis Drug
The Swedish biotech's hopes of advancing cobitolimod lie in tatters after a Phase III study of the TLR9 agonist proved futile.
Asia Deal Watch: HanAll, Daewoong Team With US Biotech In Parkinson's
Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.
AstraZeneca’s IBD Hopes Deflated Amid Evolving Market And Pipeline Competition
The major’s attempt to break into Crohn’s disease and ulcerative colitis has been cut short as a highly competitive market and pipeline, intensified by the entrance of biosimilars, renders further development of brazikumab impractical.
Servier To Refresh Neuroscience Space With New RNA-Oriented Precision Medicine Focus
The French firm’s stagnant neuroscience franchise will be revamped through a new, strategic focus on RNA-based precision medicines for neurodegenerative diseases including both small- and large-molecule drugs, the company tells Scrip.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
-
Diagnostic Imaging Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- ADMET
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice